Serum soluble TWEAK levels are decreased in treatment naive noncirrhotic chronic hepatitis B patients

Basit Öğe Kaydı
dc.contributor.authorAsil, Mehmet
dc.contributor.authorDertli, Ramazan
dc.date.accessioned2024-02-23T14:21:13Z
dc.date.available2024-02-23T14:21:13Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractThe mechanisms underlying hepatic inflammation and fibrogenesis in chronic hepatitis B (CHB) are complex and several cytokines are involved. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor superfamily which also acts as a cytokine. This study was conducted to evaluate serum soluble TWEAK (sTWEAK) levels in noncirrhotic CHB patients.Fifty-two treatment naive CHB patients and 30 healthy controls were included in the study and serum sTWEAK concentrations were measured using commercially available ELISA kits.Mean serum sTWEAK concentration was significantly lower in CHB group than healthy controls (189.663.3pg/mL in CHB group and 297.6 +/- 61.5pg/mL in control group, P<0.001). According to the degree of necroinflammation in liver biopsies mean sTWEAK concentrations were found to be 168.14 +/- 51.51, 206.96 +/- 58.51, and 223.62 +/- 78.88pg/mL in patients with mild, moderate, and severe inflammation, respectively, and the difference between groups was statistically significant (P=0.022). sTWEAK concentration was also found to be significantly higher in patients with advanced fibrosis in liver biopsy samples (169.59 +/- 52.02 and 211.17 +/- 68.22pg/mL in patients with mild and advanced fibrosis, respectively, P=0.016). Receiver operating characteristic (ROC) curves were obtained in CHB group to differentiate patients with advanced fibrosis from patients with mild fibrosis. Area under curve (AUC) was 0.676 (95% Cl; 0.526-0.825) for sTWEAK and for the specified cut-off value of 213.67pg/mL sensitivity and specificity were 60% and 81.4%, respectively. ROC curve for sTWEAK to differentiate patients with severe inflammation revealed an AUC of 0.664 (95% Cl; 0.450-0.878). A cut-off value of 243.27pg/mL yielded 54.5% sensitivity and 82.9% specificity.Serum sTWEAK concentration is decreased in treatment naive CHB patients. Further studies with simultaneous determination of circulating sTWEAK concentrations and TWEAK and factor-inducible 14 (Fn14) expressions in the liver biopsy samples would clarify the exact association of TWEAK/Fn14 pathway in the pathogenesis of CHB.en_US
dc.identifier.doi10.1097/MD.0000000000004763
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue37en_US
dc.identifier.pmid27631226en_US
dc.identifier.scopus2-s2.0-84991665924en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000004763
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13501
dc.identifier.volume95en_US
dc.identifier.wosWOS:000384461600028en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofMedicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Hepatitis Ben_US
dc.subjectFibrosisen_US
dc.subjectInflammationen_US
dc.subjectStweaken_US
dc.subjectTumor Necrosis Factor-Like Weak Inducer Of Apoptosisen_US
dc.titleSerum soluble TWEAK levels are decreased in treatment naive noncirrhotic chronic hepatitis B patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu